These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1608 related articles for article (PubMed ID: 33510460)

  • 61. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
    Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Update on Embolization Therapies for Hepatocellular Carcinoma.
    Kishore S; Friedman T; Madoff DC
    Curr Oncol Rep; 2017 Jun; 19(6):40. PubMed ID: 28421483
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immune checkpoint inhibitors for hepatocellular carcinoma.
    El Dika I; Khalil DN; Abou-Alfa GK
    Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
    [TBL] [Abstract][Full Text] [Related]  

  • 64. New progress of non-surgical treatments for hepatocellular carcinoma.
    Cheng JW; Lv Y
    Med Oncol; 2013 Mar; 30(1):381. PubMed ID: 23292867
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatocellular carcinoma: locoregional and targeted therapies.
    Wong R; Frenette C; Gish R
    Gastroenterol Clin North Am; 2011 Sep; 40(3):599-610. PubMed ID: 21893276
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation.
    Thuluvath PJ; To C; Amjad W
    Am J Gastroenterol; 2021 Jan; 116(1):57-67. PubMed ID: 33110015
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Multimodal treatment of hepatocellular carcinoma].
    Kirstein MM; Wirth TC
    Internist (Berl); 2020 Feb; 61(2):164-169. PubMed ID: 31919533
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Transarterial chemoembolization and radioembolization.
    Sangro B; Salem R
    Semin Liver Dis; 2014 Nov; 34(4):435-43. PubMed ID: 25369305
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.
    Minocha J; Salem R; Lewandowski RJ
    Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adjuvant cytokine-induced killer cells with minimally invasive therapies augmented therapeutic efficacy of unresectable hepatocellular carcinoma.
    Huang ZM; Lai CX; Zuo MX; An C; Wang XC; Huang JH; Ning E
    J Cancer Res Ther; 2020; 16(7):1603-1610. PubMed ID: 33565506
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions.
    Kumar Y; Sharma P; Bhatt N; Hooda K
    Asian Pac J Cancer Prev; 2016; 17(2):473-8. PubMed ID: 26925630
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    Brandi N; Renzulli M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239941
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy.
    Lu SD; Li L; Liang XM; Chen W; Chen FL; Fan LL; Ahir BK; Zhang WG; Zhong JH
    Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1077-1088. PubMed ID: 31648568
    [No Abstract]   [Full Text] [Related]  

  • 75. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.
    Alnammi M; Wortman J; Therrien J; Afnan J
    Abdom Radiol (NY); 2022 Jul; 47(7):2299-2313. PubMed ID: 35524803
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Liver-directed therapy for hepatocellular carcinoma.
    Narsinh KH; Duncan DP; Newton IG; Minocha J; Rose SC
    Abdom Radiol (NY); 2018 Jan; 43(1):203-217. PubMed ID: 29230556
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Systemic therapies for hepatocellular carcinoma.
    Ge S; Huang D
    Drug Discov Ther; 2015 Oct; 9(5):352-62. PubMed ID: 26632544
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma.
    Jianyong L; Jinjing Z; Lunan Y; Jingqiang Z; Wentao W; Yong Z; Bo L; Tianfu W; Jiaying Y
    Sci Rep; 2017 Feb; 7():41624. PubMed ID: 28155861
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Percutaneous ablation for perivascular hepatocellular carcinoma: Refining the current status based on emerging evidence and future perspectives.
    Kang TW; Lim HK; Cha DI
    World J Gastroenterol; 2018 Dec; 24(47):5331-5337. PubMed ID: 30598578
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches.
    Lindemann J; Yu J; Doyle MBM
    Surg Oncol Clin N Am; 2024 Jan; 33(1):143-158. PubMed ID: 37945140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.